Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Common Equity (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Common Equity data on record, last reported at -$33.9 million in Q4 2025.

  • For Q4 2025, Common Equity fell 30.77% year-over-year to -$33.9 million; the TTM value through Dec 2025 reached -$33.9 million, down 30.77%, while the annual FY2025 figure was -$33.9 million, 30.77% down from the prior year.
  • Common Equity reached -$33.9 million in Q4 2025 per TLSI's latest filing, down from -$26.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $8.3 million in Q3 2023 and bottomed at -$198.4 million in Q2 2023.
  • Average Common Equity over 4 years is -$77.4 million, with a median of -$34.1 million recorded in 2025.
  • Peak YoY movement for Common Equity: surged 105.39% in 2023, then crashed 346.43% in 2024.
  • A 4-year view of Common Equity shows it stood at -$177.1 million in 2022, then soared by 84.72% to -$27.1 million in 2023, then increased by 4.33% to -$25.9 million in 2024, then tumbled by 30.77% to -$33.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$33.9 million in Q4 2025, -$26.7 million in Q3 2025, and -$19.4 million in Q2 2025.